Thank you as always for your insights! It sounds like you could get you're wish with the rolling launch for vitiligo into the biggest states first.
I missed Incyte's very impressive sales. It's a good indication of the vitiligo market and potential revenue Avita could receive for a safe, one and done treatment. Another good indication of the demand was the recruitment of the 109 patients for the TONE trial in around 5 months.
In saying that, I'm trying not to to get too excited about the pipeline indications/expansions until they've look to deliver on (or exceed) this year's revenue guidance.
I'm loving the informed discussion. I encourage everyone to share their knowledge and thoughts (positive and negative).
Thank you as always for your insights! It sounds like you could...
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.70 |
Change
-0.010(0.37%) |
Mkt cap ! $167.8M | |||
| Open | High | Low | Value | Volume |
| $2.73 | $2.74 | $2.68 | $913.8K | 336.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 3704 | $2.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.70 | 10305 | 2 |
View Market Depth
| Last trade - 16.10pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$2.71 |
Change
-0.010 ( 0.90 %) |
||||
| Open | High | Low | Volume | ||
| $2.73 | $2.74 | $2.68 | 11334 | ||
| Last updated 15.59pm 10/05/2024 ? | |||||
| AVH (ASX) Chart |